Novartis plans to launch three more biosimilars by 2020
Sandoz, a Novartis division, announced that the EMA's Committee for Medicinal Products for Human Use has adopted positive opinions, separately recommending the approval of both Sandoz' biosimilar rituximab and biosimilar etanercept in Europe, to treat the same indications as their respective reference medicines. The company added: "Sandoz is committed to increasing patient access to high-quality, life-enhancing biosimilars. It is the pioneer and global leader in biosimilars, and currently markets three biosimilars worldwide. Sandoz has a leading biosimilar pipeline and, in addition to biosimilar rituximab and etanercept, plans to launch three more biosimilars of major oncology and immunology biologics across key geographies by 2020."